Xilio Therapeutics Inc [NASDAQ: XLO] gained 7.81% or 0.05 points to close at $0.75 with a heavy trading volume of 10209934 shares.
It opened the trading session at $0.725, the shares rose to $0.8 and dropped to $0.721, the range by which the price of stock traded the whole day. The daily chart for XLO points out that the company has recorded -11.23% loss over the past six months.
If we look at the average trading volume of 410.87K shares, XLO reached to a volume of 10209934 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Xilio Therapeutics Inc [XLO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XLO shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XLO stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Xilio Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 06, 2025. While these analysts kept the previous recommendation, Chardan Capital Markets raised their target price to Buy. The new note on the price target was released on December 21, 2022, representing the official price target for Xilio Therapeutics Inc stock. Previously, the target price had yet another raise to $36, while H.C. Wainwright analysts kept a Buy rating on XLO stock.
The Price to Book ratio for the last quarter was 5.50, with the Price to Cash per share for the same quarter was set at 2.35.
Trading performance analysis for XLO stock
Xilio Therapeutics Inc [XLO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.43. With this latest performance, XLO shares gained by 13.12% in over the last four-week period, additionally sinking by -11.23% over the last 6 months – not to mention a drop of -21.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XLO stock in for the last two-week period is set at 63.05, with the RSI for the last a single of trading hit 0.0429, and the three-weeks RSI is set at 0.0411 for Xilio Therapeutics Inc [XLO]. The present Moving Average for the last 50 days of trading for this stock 0.6973, while it was recorded at 0.7175 for the last single week of trading, and 0.8205 for the last 200 days.
Xilio Therapeutics Inc [XLO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Xilio Therapeutics Inc [XLO] shares currently have an operating margin of -377.63% and a Gross Margin at 88.52%. Xilio Therapeutics Inc’s Net Margin is presently recorded at -374.79%.
Xilio Therapeutics Inc (XLO) Capital Structure & Debt Analysis
According to recent financial data for Xilio Therapeutics Inc. ( XLO), the Return on Equity (ROE) stands at -277.74%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -50.27%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Xilio Therapeutics Inc’s Return on Invested Capital (ROIC) is -420.48%, showcasing its effectiveness in deploying capital for earnings.
Xilio Therapeutics Inc (XLO) Efficiency & Liquidity Metrics
Based on Xilio Therapeutics Inc’s (XLO) latest financial statements, the Debt-to-Equity Ratio is 1.07%, indicating its reliance on debt financing relative to shareholder equity.
Xilio Therapeutics Inc (XLO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Xilio Therapeutics Inc. (XLO) effectively leverages its workforce, generating an average of -$878437.5 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.32% and a Quick Ratio of 2.32%, indicating strong ability to cover short-term liabilities.
Xilio Therapeutics Inc [XLO]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Xilio Therapeutics Inc posted -0.22/share EPS, while the average EPS was predicted by analysts to be reported at -0.3/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.08. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for XLO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Xilio Therapeutics Inc go to 15.19%.
An analysis of Institutional ownership at Xilio Therapeutics Inc [XLO]
There are presently around $25.42%, or 46.82%% of XLO stock, in the hands of institutional investors. The top three institutional holders of XLO stocks are: BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with ownership of 3.79 million shares, which is approximately 13.5618%. ROCK SPRINGS CAPITAL MANAGEMENT LP, holding 3.0 million shares of the stock with an approximate value of $$2.85 million in XLO stocks shares; and ROCK SPRINGS CAPITAL MANAGEMENT LP, currently with $$1.37 million in XLO stock with ownership which is approximately 5.1641%.
